Results 71 to 80 of about 135,991 (315)

A Physiological Microfluidic Blood–Brain‐Barrier Model for In Vitro Study of Nanoparticle Trafficking and Accumulation

open access: yesAdvanced Healthcare Materials, EarlyView.
A human microfluidic blood‐brain barrier (mBBB) model enables spatially resolved comparison of nanoparticle trafficking. Extracellular vesicles (EVs), liposomes, and nanoplastics exhibit distinct transport and disruption behaviors, revealing that membrane composition and uptake pathways govern BBB interaction.
Bryan B. Nguyen   +9 more
wiley   +1 more source

The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia--Volume II: Technical Report [PDF]

open access: yes
(see SEDAP 70 for abstract)reference pricing,prescription drugs,ACE inhibitors,calcium channel blockers,nitrates,pharmaceutical cost control,seniors,user ...
Adrian R. Levy   +4 more
core  

Nanozymes at the Bio‐Nano Interface: From Synthesis, Defect Engineering, Catalytic Behavior in Biological Microenvironments, and Biosafety Implications

open access: yesAdvanced Materials Interfaces, EarlyView.
Nanozymes (NZs) have emerged as versatile artificial enzymes with tunable catalytic properties driven by atomic coordination, defect engineering, and surface chemistry. This review presents a bio–nano interface framework linking synthesis strategies, structural design, and catalytic behavior within complex biological microenvironments.
Karen Guadalupe Quintero‐Garrido   +6 more
wiley   +1 more source

How New Fees Are Affecting the Producer Price Index for Air Travel [PDF]

open access: yes, 2012
Since 2001, the airline industry has been affected by a number of external shocks, including terrorist attacks, volatile fuel prices, periods of challenging economic times, and an uncertain regulatory environment.
Bureau of Labor Statistics
core   +1 more source

Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980–2022

open access: yesScientific Reports
U.S. laws enacted since 1983 have aimed to enhance the development and marketing of new pharmaceutical products. We thoroughly characterized all new molecular entities, therapeutic biologics, and gene and cell therapies approved by the US Food and Drug ...
Enrique Seoane-Vazquez   +2 more
doaj   +1 more source

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper   +546 more
wiley   +1 more source

Recurrent costs in primary health care in Ethiopia: facility and disease specific unit costs and their components in government primary hospitals and health centers

open access: yesBMC Health Services Research, 2020
Background Continued investment, especially from domestic financing, is needed for Ethiopia to achieve universal health coverage and a sustainable health system over time.
Anubhav Agarwal   +5 more
doaj   +1 more source

The human right to medicines [PDF]

open access: yes, 2008
This article considers the component of the right to the highest standard of health that relates to medicines, including essential medicines. Using the right-to-health analytical framework that has been developed in recent years, the first section ...
Hunt, PH, Khosla, R
core  

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo   +38 more
wiley   +1 more source

Home - About - Disclaimer - Privacy